Please note that the details of this Challenge are no longer open. This challenge is under evaluation and is no longer accepting new submissions. You can:
Challenge AstraZeneca Challenge: Improving the Targeting and Transduction Efficiency of Adeno-Associated Viral Vectors

AstraZeneca Challenge: Improving the Targeting and Transduction Efficiency of Adeno-Associated Viral Vectors

Award: $25,000 USD
STATUS: Under Eval
Active Solvers: 138
Posted: Aug 16 2019
Challenge ID: 9934220
 
Team Project Rooms are available on this Challenge Team Share Challenge Share
Abstract

Adeno-associated virus (AAV) is a non-enveloped virus that infects humans with no known pathogenicity. With the ability to infect both dividing and non-dividing cells, AAVs are being studied as promising vehicles for targeted gene therapy. Therefore, AstraZeneca desires innovative approaches to improve not only the targeting, but also the transduction efficiency of AAV vectors.

This Theoretical Challenge requires only a written proposal.

Overview

As AAVs garner more attention as a platform for gene therapy, the number of translational studies in which AAV vectors have been used for in vivo gene transfer has steadily increased and more clinical trial data have been generated. While AAV vectors maintain a good safety profile, they could benefit from optimization in terms of transduction efficiency and tissue-specific targeting, thereby increasing the therapeutic window and reducing off-target side effects. To support AstraZeneca’s research in our core therapeutic areas, we are seeking innovative strategies to enhance the targeted delivery of AAV vectors to particular tissues or organs such as heart, kidney, and lung cells with much improved transduction efficiency.

This is a Theoretical Challenge that requires only a written proposal to be submitted. The Challenge award will be contingent upon Seeker’s theoretical evaluation of the quality of the data analysis as detailed in the submission.

To receive an award, the Solvers will not have to transfer their exclusive IP rights to the Seeker. Instead, Solvers will grant to the Seeker a non-exclusive license to practice their solutions. 

Submissions to this Challenge must be received by 11:59 PM (US Eastern Time) on October 15, 2019. 

Late submissions will not be considered.

ABOUT THE SEEKER

AstraZeneca is a global, science-led, biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three main therapy areas – Oncology, Cardiovascular & Metabolic Diseases and Respiratory.  AstraZeneca also is selectively active in the areas of autoimmunity, neuroscience and infection. As an innovation-driven research organization, AstraZeneca recognizes that great ideas come from many sources. Open innovation is an avenue by which ideas can be shared and AstraZeneca recently launched a pavilion to further its commitment to facilitate the advancement of pharmaceutical research.

What is InnoCentive?
InnoCentive is the global innovation marketplace where creative minds solve some of the world's most important problems for cash awards up to $1 million. Commercial, governmental and humanitarian organizations engage with InnoCentive to solve problems that can impact humankind in areas ranging from the environment to medical advancements.

What is a Theoretical-Licensing Challenge?

An InnoCentive Theoretical Challenge builds upon an idea but is not yet a proof of concept. A solution to a Theoretical Challenge will solidify the Solver's concept with detailed descriptions, specifications and requirements necessary to bringing a good idea closer to becoming an actual product or service.

This Challenge is a Theoretical-Licensing Challenge, meaning that the Seeker is requesting non-exclusive rights to use the winning solution. By contrast, Theoretical-IP Transfer means that Solvers must relinquish all rights to the Intellectual Property (IP) for which they are awarded. For these forms of a Theoretical Challenge, Solvers that do not win retain the rights to their solution after the evaluation period is complete. The Seeker retains no rights to any IP not awarded.

Share This Challenge